Ed Miseta - Chief Editor, Clinical Leader & Outsourced Pharma
How Portage Biotech Created A Lean, New Drug Development Model
Dr. Ian Walters noticed that Big Pharma companies often would lament that small biotechs did not develop drugs the same way as their larger counterparts. He set out to change that. Continue Reading..
A New Funding Model For A New Approach To Pain
The business model CEO Dr. Hernan Bazan and his colleagues put in place at South Rampart Pharma was not typical for a small biotech firm. Continue Reading..
How Are DCTs Impacting Your Clinical Sites?
Where do your sites stand on DCTs? For this article, we spoke with three site experts who discussed the pain points of DCTs, including costs, budgeting, training, support, staffing, resources, and more. Continue Reading..
What Is A Risk-Based Approach To CRO Oversight?
Ian Wyglendowski, the head of strategic clinical partnering at UCB, recommends taking a risk-based approach to CRO oversight, and gives specifics that you can implement. Continue Reading..
How To Become A Sponsor Of Choice For Your CRO Partners
Becoming a true sponsor of choice involves much more than simply saying the words. Drug discovery is a tough business and there are many parts that must seamlessly interact to get a product to regulatory approval. Continue Reading..
Why I’m Thankful For Sponsors And CROs
There are many patients out there who depend on those efforts and the amazing medicines that result from them. I am now one of them. Continue Reading..
Takeda’s Mission To Improve Communication With Patients, Sites, And CROs
Being a better partner for your patients, sites, and CROs begins with effective communication. When Karen Correa joined Takeda as VP, head of global clinical operations, she made improved communications her top priority. Continue Reading..
Do Patients Really Want Hybrid Clinical Trials?
“Decentralized and hybrid trials offer convenience, but that convenience must be balanced with individual preferences. We are entering an age of more personalized and customized participant experiences, and we have to figure out how to manage that,” says Ken Getz of CISCRP. Continue Reading..
Is Janssen’s Pathway Approach The Future Of Drug Development
Two Janssen execs talk about the future of what they call a pathway approach to developing new medicines, which attempts to match the biology of a pathway to unmet medical need for patients, across a broad range of immune-mediated, inflammatory disease. Continue Reading..
From Fusion Energy To Med Device … To Drug Developer?
TAE Life Sciences wanted to create a combination product that brought together its neutron beam with a drug that delivers boron to cancer cells. But, the company didn’t want to be in a position where it relied on another company for the drug needed. Continue Reading..